Errata (DOI:10.1016/S1474-4422(08)70140-6);CSF hypocretin-1 assessment in sleep and neurological disorders

The Lancet Neurology

Volumn 7, Issue 7, 2008, Pages 649-662

  Bourgin, Patrice ^a,b   Zeitzer, Jamie M ^a,c   Mignot, Emmanuel ^a,d  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQB1 ANTIGEN; LEVODOPA; OREXIN A;

CATALEPSY; CEREBROSPINAL FLUID ANALYSIS; COMORBIDITY; DEGENERATIVE DISEASE; GENETIC ANALYSIS; GENETIC DISORDER; HLA TYPING; HUMAN; HYPERSOMNIA; LUMBAR PUNCTURE; MYOTONIC DYSTROPHY; NARCOLEPSY; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEFICIENCY; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; TRAUMATIC BRAIN INJURY;

EID: 50049088124     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70182-0     Document Type: Erratum

References (140)

1. de Lecea L., Kilduff T., Peyron C., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95 (1998) 322-327
2. Sakurai T., Amemiya A., Ishii M., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (1998) 573-585
3. Thannickal T., Moore R., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 (2000) 469-474
4. Eriksson K., Sergeeva O., Brown R., and Haas H. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 21 (2001) 9273-9279
5. Korotkova T., Sergeeva O., Eriksson K., Haas H., and Brown R. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci 23 (2003) 7-11
6. Bourgin P., Huitron-Resendiz S., Spier A., et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 20 (2000) 7760-7765
7. Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev 9 (2005) 231-241
8. Ganjavi H., and Shapiro C. Hypocretin/orexin: a molecular link between sleep, energy regulation, and pleasure. J Neuropsychiatry Clin Neurosci 19 (2007) 413-419
9. In: Bassetti C., Billiard M., and Mignot E. (Eds). Narcolepsy and hypersomnia (2007), Informa Healthcare, New York 359-374
10. Dauvilliers Y., Arnulf I., and Mignot E. Narcolepsy with cataplexy. Lancet 369 (2007) 499-511
11. Anic-Labat S., Guilleminault C., Kraemer H., Meehan J., Arrigoni J., and Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 22 (1999) 77-87
12. Szklo-Coxe M., Young T., Finn L., and Mignot E. Automatic behavior, sleep paralysis, hypnagogic hallucinations, cataplexy: narcolepsy spectrum and aternate etiology. In: Bassetti C., Billiard M., and Mignot E. (Eds). Narcolepsy and hypersomnia (2007), Informa Healthcare, New York 133-150
13. American Academy of Sleep Medicine. International classification of sleep disorders, 2nd edition: diagnostic and coding manual (2005), American Academy of Sleep Medicine, Westchester, IL
14. Billiard M. Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the international classification of sleep disorders. Sleep Med Rev 11 (2007) 377-388 2nd edition
15. Mignot E., Lin L., Rogers W., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68 (2001) 686-699
16. Mignot E., Hayduk R., Black J., Grumet F., and Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20 (1997) 1012-1020
17. Lin L., Faraco J., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (1999) 365-376
18. Chemelli R., Willie J., Sinton C., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 (1999) 437-451
19. Nishino S., Ripley B., Overeem S., Lammers G., and Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355 (2000) 39-40
20. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 (2000) 991-997
21. Thannickal T., Siegel J., Nienhuis R., and Moore R. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 13 (2003) 340-351
22. Lin L., and Mignot E. Human leukocyte antigen and narcolepsy: present status and relationship with familial history and hypocretin deficiency. In: Bassetti C., Billiard M., and Mignot E. (Eds). Narcolepsy and hypersomnia (2007), Informa Health Care, New York 411-426
23. Mignot E., Lammers G., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59 (2002) 1553-1562
24. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 suppl 1 (1998) S16-S22
25. Scammell T. The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy. Sleep 29 (2006) 601-602
26. Ripley B., Overeem S., Fujiki N., et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57 (2001) 2253-2258
27. Krahn L., Pankratz V., Oliver L., Boeve B., and Silber M. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 25 (2002) 733-736
28. Dauvilliers Y., Baumann C., Carlander B., et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 74 (2003) 1667-1673
29. Khatami R., Maret S., Werth E., et al. Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. Lancet 363 (2004) 1199-1200
30. Dauvilliers Y., Maret S., Bassetti C., et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 62 (2004) 2137-2138
31. Mignot E. CSF hypocretin-1/orexin-A in narcolepsy: technical aspects and clinical experience in the United States. In: Bassetti C, Billiard M, Mignot E, eds. Narcolepsy and hypersomnia: Informa Healthcare, 2007: 287-301.
32. Nishino S., and Mignot E. Plasma orexin-A is lower in patients with narcolepsy. Sleep Med 3 (2002) 377-378
33. Hartwig G., Harsh J., Ripley B., Nishino S., and Mignot E. Low cerebrospinal fluid hypocretin levels found in familial narcolepsy. Sleep Med 2 (2001) 451-453
34. Kanbayashi T., Inoue Y., Chiba S., et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 11 (2002) 91-93
35. Bassetti C., Gugger M., Bischof M., et al. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med 4 (2003) 7-12
36. Hong S., Lin L., Jeong J., et al. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep 29 (2006) 1429-1438
37. Heier M., Evsiukova T., Vilming S., Gjerstad M., Schrader H., and Gautvik K. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 30 (2007) 969-973
38. Oka Y., Kanbayashi T., Mezaki T., et al. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis. J Neurol 251 (2004) 885-886
39. Oka Y., Inoue Y., Kanbayashi T., et al. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. Sleep 29 (2006) 1439-1443
40. Mignot E., Chen W., and Black J. On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep 26 (2003) 646-649
41. Kubota H., Kanbayashi T., Tanabe Y., et al. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 26 (2003) 555-557
42. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 60 (2006) 153
43. Melberg A., Ripley B., Lin L., Hetta J., Mignot E., and Nishino S. Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol 49 (2001) 136-137
44. Dalal M., Schuld A., and Pollmacher T. Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy. J Sleep Res 11 (2002) 273
45. Singh M., Drake C., and Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 29 (2006) 890-895
46. Mignot E., Lin L., Finn L., et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 129 (2006) 1609-1623
47. Komada Y., Inoue Y., Mukai J., Shirakawa S., Takahashi K., and Honda Y. Difference in the characteristics of subjective and objective sleepiness between narcolepsy and essential hypersomnia. Psychiatry Clin Neurosci 59 (2005) 194-199
48. Kanbayashi T., Kodama T., Hondo H., et al. CSF histamine and noradrenaline contents in narcolepsy and other sleep disorders. Sleep 27 suppl (2004) A236
49. Nishino S., Sakurai E., Nevisimalova S., et al. CSF histamine content is decreased in hypocretin-deficient human narcolepsy [abstract]. Sleep 25 suppl (2002) A476
50. Arnulf I., Zeitzer J., File J., Farber N., and Mignot E. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 128 (2005) 2763-2776
51. Arnulf I., Lin L., Gadoth N., et al. Kleine-Levin syndrome: a study of 108 patients. Ann Neurol 63 (2008) 482-493
52. Dauvilliers Y., Mayer G., Lecendreux M., et al. Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. Neurology 59 (2002) 1739-1745
53. Katz J., and Ropper A. Familial Kleine-Levin syndrome: two siblings with unusually long hypersomnic spells. Arch Neurol 59 (2002) 1959-1961
54. Podesta C., Ferreras M., Mozzi M., Bassetti C., Dauvilliers Y., and Billiard M. Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements. Sleep Med 7 (2006) 649-651
55. Kanbayashi T., Inoue Y., Kawanishi K., et al. CSF hypocretin measures in patients with obstructive sleep apnea. J Sleep Res 12 (2003) 339-341
56. Winkelmann J., Schormair B., Lichtner P., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 39 (2007) 1000-1006
57. Stefansson H., Rye D., Hicks A., et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 357 (2007) 639-647
58. Mignot E. A step forward for restless legs syndrome. Nat Genet 39 (2007) 938-939
59. Gamaldo C., and Earley C. Restless legs syndrome: a clinical update. Chest 130 (2006) 1596-1604
60. Alberto C., Trask R., Quinlan M., and Hirasawa M. Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. J Neurosci 26 (2006) 10043-10050
61. Narita M., Nagumo Y., Hashimoto S., et al. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 26 (2006) 398-405
62. Allen R., Mignot E., Ripley B., Nishino S., and Earley C. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 59 (2002) 639-641
63. Stiasny-Kolster K., Mignot E., Ling L., Moller J., Cassel W., and Oertel W. CSF hypocretin-1 levels in restless legs syndrome. Neurology 61 (2003) 1426-1429
64. Von Economo C. Encephalitis lethargica. Weiner Medizinische Wochenschrift 73 (1923) 777-782 835-38, 1113-18.
65. Aldrich M., and Naylor M. Narcolepsy associated with lesions of the diencephalon. Neurology 39 (1989) 1505-1508
66. Nishino S., and Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 9 (2005) 269-310
67. Mathis J., Hess C., and Bassetti C. Isolated mediotegmental lesion causing narcolepsy and rapid eye movement sleep behaviour disorder: a case evidencing a common pathway in narcolepsy and rapid eye movement sleep behaviour disorder. J Neurol Neurosurg Psychiatry 78 (2007) 427-429
68. Tohyama J., Kanazawa O., Akasaka N., and Kamimura T. A case of bilateral paramedian thalamic infarction in childhood with the sensory disturbance and the sensory loss of taste [in Japanese]. No To Hattatsu 36 (2004) 65-69
69. Scammell T., Nishino S., Mignot E., and Saper C. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 56 (2001) 1751-1753
70. Arii J., Kanbayashi T., Tanabe Y., Ono J., Nishino S., and Kohno Y. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 56 (2001) 1775-1776
71. Tachibana N., Taniike M., Okinaga T., Ripley B., Mignot E., and Nishino S. Hypersomnolence and increased REM sleep with low cerebrospinal fluid hypocretin level in a patient after removal of craniopharyngioma. Sleep Med 6 (2005) 567-569
72. Marcus C., Trescher W., Halbower A., and Lutz J. Secondary narcolepsy in children with brain tumors. Sleep 25 (2002) 435-439
73. van der Klaauw A., Dekkers O., Pereira A., van Kralingen K., and Romijn J. Increased daytime somnolence despite normal sleep patterns in patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92 (2007) 3898-3903
74. Dempsey O., McGeoch P., de Silva R., and Douglas N. Acquired narcolepsy in an acromegalic patient who underwent pituitary irradiation. Neurology 61 (2003) 537-540
75. Celius E., Harbo H., Egeland T., Vartdal F., Vandvik B., and Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 178 (2000) 132-135
76. Nozaki H., Katada S., Sato M., Tanaka K., and Nishizawa M. A case with hypersomnia and paresthesia due to diffuse MS lesions from hypothalamus to spine. Rinsho Shinkeigaku 44 (2004) 59
77. Ebrahim I., Semra Y., De Lacy S., et al. CSF hypocretin (orexin) in neurological and psychiatric conditions. J Sleep Res 12 (2003) 83-84
78. Kato T., Kanbayashi T., Yamamoto K., et al. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med 42 (2003) 743-745
79. Overeem S., Dalmau J., Bataller L., et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 62 (2004) 138-140
80. Dalmau J., Graus F., Villarejo A., et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 (2004) 1831-1844
81. Compta Y., Iranzo A., Santamaria J., Casamitjana R., and Graus F. REM sleep behavior disorder and narcoleptic features in anti-Ma2-associated encephalitis. Sleep 30 (2007) 767-769
82. Nishino S., Kanbayashi T., Fujiki N., et al. CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology 61 (2003) 823-825
83. Cochen V., Arnulf I., Demeret S., et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndrome. Brain 128 (2005) 2535-2545
84. Smit L., Lammers G., and Catsman-Berrevoets C. Cataplexy leading to the diagnosis of Niemann-Pick disease type C. Pediatr Neurol 35 (2006) 82-84
85. Vankova J., Stepanova I., Jech R., et al. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 26 (2003) 427-430
86. Kanbayashi T., Abe M., Fujimoto S., et al. Hypocretin deficiency in Niemann-Pick type C with cataplexy. Neuropediatrics 34 (2003) 52-53
87. Oyama K., Takahashi T., Shoji Y., et al. Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid. Tohoku J Exp Med 209 (2006) 263-267
88. Martinez-Rodriguez J., Lin L., Iranzo A., et al. Decreased hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 26 (2003) 287-290
89. Ciafaloni E., Mignot E., Sansone V., et al. The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology 70 (2008) 226-230
90. Overeem S., van Hilten J., Ripley B., Mignot E., Nishino S., and Lammers G. Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 58 (2002) 498-499
91. Yasui K., Inoue Y., Kanbayashi T., Nomura T., Kusumi M., and Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 250 (2006) 120-123
92. Baumann C., Ferini-Strambi L., Waldvogel D., Werth E., and Bassetti C. Parkinsonism with excessive daytime sleepiness-a narcolepsy-like disorder?. J Neurol 252 (2005) 139-145
93. Maeda T., Nagata K., Kondo H., and Kanbayashi T. Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level. Sleep Med 7 (2006) 662
94. Drouot X., Moutereau S., Nguyen J., et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61 (2003) 540-543
95. Ebrahim I., Sharief M., de Lacy S., et al. Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia. J Neurol Neurosurg Psychiatry 74 (2003) 127-130
96. Lagrange A., Blaivas M., Gomez-Hassan D., and Malow B. Rasmussen's syndrome and new-onset narcolepsy, cataplexy, and epilepsy in an adult. Epilepsy Behav 4 (2003) 788-792
97. Carlander B., Vincent T., Le Floch A., Pageot N., Camu W., and Dauvilliers Y. Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes. J Neurol Neurosurg Psychiatry 79 (2008) 333-334
98. Nozaki H., Shimohata T., Kanbayashi T., et al. A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. Sleep Med (2008) 10.1016/j.sleep.2007.11.022 published online Jan 26.
99. Yoshikawa S., Suzuki S., Kanbayashi T., Nishino S., and Tamai H. Hypersomnia and low cerebrospinal fluid hypocretin levels in acute disseminated encephalomyelitis. Pediatr Neurol 31 (2004) 367-370
100. Aldrich M. Diagnostic aspects of narcolepsy. Neurology 50 suppl 1 (1998) S2-S7
101. Kubota H., Kanbayashi T., Tanabe Y., Takanashi J., and Kohno Y. A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J Child Neurol 17 (2002) 537-539
102. Arii J., Kanbayashi T., Tanabe Y., et al. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 63 (2004) 2440-2442
103. Kanbayashi T., Ishiguro H., Aizawa R., et al. Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain-Barré syndrome. Psychiatry Clin Neurosci 56 (2002) 273-274
104. Baumann C., and Bassetti C. CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology 62 (2004) 2337
105. Guilleminault C., Yuen K., Gulevich M., Karadeniz D., Leger D., and Philip P. Hypersomnia after head-neck trauma: a medicolegal dilemma. Neurology 54 (2000) 653-659
106. Baumann C., Stocker R., Imhof H., et al. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 65 (2005) 147-149
107. Dohi K., Ripley B., Fujiki N., et al. CSF orexin-A/hypocretin-1 concentrations in patients with intracerebral hemorrhage (ICH). Regul Pept 145 (2008) 60-64
108. Baumann C., Werth E., Stocker R., Ludwig S., and Bassetti C. Sleep-wake disturbances 6 months after traumatic brain injury: a prospective study. Brain 130 (2007) 1873-1883
109. Parkes J. Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome. J Sleep Res 8 suppl 1 (1999) 14-22
110. Havaligi N., Matadeen-Ali C., Khurana D., Marks H., and Kothare S. Treatment of drop attacks in Coffin-Lowry syndrome with the use of sodium oxybate. Pediatr Neurol 37 (2007) 373-374
111. Challamel M., Mazzola M., Nevsimalova S., Cannard C., Louis J., and Revol M. Narcolepsy in children. Sleep 17 suppl (1994) S17-S20
112. Nevsimalova S., Vankova J., Stepanova I., Seemanova E., Mignot E., and Nishino S. Hypocretin deficiency in Prader-Willi syndrome. Eur J Neurol 12 (2005) 70-72
113. Fronczek R., Lammers G., Balesar R., Unmehopa U., and Swaab D. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. J Clin Endocrinol Metab 90 (2005) 5466-5470
114. Arnulf I., Konofal E., Merino-Andreu M., et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58 (2002) 1019-1024
115. Arnulf I., Bonnet A., Damier P., et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55 (2000) 281-288
116. Yesavage J., Friedman L., Ancoli-Israel S., et al. Development of diagnostic criteria for defining sleep disturbance in Alzheimer's disease. J Geriatr Psychiatry Neurol 16 (2003) 131-139
117. Cooke J., Liu L., Natarajan L., et al. The effect of sleep-disordered breathing on stages of sleep in patients with Alzheimer's disease. Behav Sleep Med 4 (2006) 219-227
118. Brotini S., and Gigli G. Epidemiology and clinical features of sleep disorders in extrapyramidal disease. Sleep Med 5 (2004) 169-179
119. Petit D., Gagnon J., Fantini M., Ferini-Strambi L., and Montplaisir J. Sleep and quantitative EEG in neurodegenerative disorders. J Psychosom Res 56 (2004) 487-496
120. Petersen A., Gil J., Maat-Schieman M., et al. Orexin loss in Huntington's disease. Hum Mol Genet 14 (2005) 39-47
121. Petersen A., and Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 24 (2006) 961-967
122. Baumann C., Hersberger M., and Bassetti C. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol 253 (2006) 1232-1233
123. Bjorkqvist M., Petersen A., Nielsen J., et al. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin Genet 70 (2006) 78-79
124. Gaus S., Lin L., and Mignot E. CSF hypocretin levels are normal in Huntington's disease patients. Sleep 28 (2005) 1607-1608
125. Meier A., Mollenhauer B., Cohrs S., et al. Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. Brain Res 1063 (2005) 201-203
126. Gerashchenko D., Murillo-Rodriguez E., Lin L., et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 184 (2003) 1010-1016
127. Zhang S., Lin L., Kaur S., et al. The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Neuroscience 148 (2007) 34-43
128. Desarnaud F., Murillo-Rodriguez E., Lin L., et al. The diurnal rhythm of hypocretin in young and old F344 rats. Sleep 27 (2004) 851-856
129. Friedman L., Zeitzer J., Lin L., et al. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 68 (2007) 793-794
130. Fronczek R., Overeem S., Lee S., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130 (2007) 1577-1585
131. Thannickal T., Lai Y., and Siegel J. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 (2007) 1586-1595
132. Hoehn M., and Yahr M. Parkinsonism: onset, progression, and mortality. 1967. Neurology 57 suppl 3 (2001) S11-S26
133. Baumann C., Dauvilliers Y., Mignot E., and Bassetti C. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur Neurol 52 (2004) 73-76
134. Martinez-Rodriguez J., Seppi K., Cardozo A., et al. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. Mov Disord 22 (2007) 1822-1824
135. Abdo W., Bloem B., Kremer H., Lammers G., Verbeek M., and Overeem S. CSF hypocretin-1 levels are normal in multiple-system atrophy. Parkinsonism Relat Disord (2007) 10.1016/j.parkreldis.2007.08.012 published online Oct 30.
136. Lin L., Bassetti C., Lammers G., et al. Guidelines for the appropriate use of CSF measurements to diagnose narcolepsy. In: Bassetti C., Billiard M., and Mignot E. (Eds). Narcolepsy and hypersomnia (2007), Informa Healthcare, New York 663-670
137. Williams R., Jensen L., Verkhratsky A., Fugger L., and Burdakov D. Control of hypothalamic orexin neurons by acid and CO2. Proc Natl Acad Sci USA 104 (2007) 10685-10690
138. Wu X., Gao J., Yan J., Owyang C., and Li Y. Hypothalamus-brain stem circuitry responsible for vagal efferent signaling to the pancreas evoked by hypoglycemia in rat. J Neurophysiol 91 (2004) 1734-1747
139. Doherty M., Watson N., Hallam D., Chandler W., and Longstreth Jr. W. Ventricular cerebrospinal fluid hypocretin-1 inversely correlates with glucose levels in cerebrospinal fluid and serum from patients with neurological injuries. Neurocrit Care 3 (2005) 230-233
140. Voderholzer U., Riemann D., Gann H., et al. Transient total sleep loss in cerebral Whipple's disease: a longitudinal study. J Sleep Res 11 (2002) 321-329